Ginkgo Bioworks Holdings, Inc. with ticker code (DNA) have now 7 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 5 and 1.75 and has a mean target at $3.59. Given that the stocks previous close was at $1.24 this would imply there is now a potential upside of 189.5%. It’s also worth noting that there is a 50 day moving average of $1.67 and the 200 day moving average is $2.44. The market cap for the company is $2,798m. You can visit the company’s website by visiting: https://www.ginkgobioworks.com
The potential market cap would be $8,101m based on the market concensus.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
The company is not paying dividends at this time.
